Bispecific Antibodies in Cancer Care: Practical Guidance for the Multidisciplinary Team (Minneapolis)

Eden Prairie, MN US
September 17, 2025

Overview

This interactive, 2-hour CME/CE-certified symposium will equip the multidisciplinary oncology team with practical strategies for integrating bispecific antibodies into the care of patients with cancer. Through expert-led presentations, panel discussions, case examples, and audience engagement, participants will explore:

  • Current and emerging bispecific therapies
  • Strategies for toxicity mitigation and management
  • Transitioning bispecific administration from inpatient to outpatient setting

The program aims to provide actionable insights for both academic and community-based cancer centers to address logistical, resourcing, and patient-care considerations to support the development of an outpatient clinic.

In this how-to session, learners will:

  • Interact with national and local/regional experts in bispecific care
  • Receive tips to streamline and avoid errors in the design of an outpatient bispecific clinic
  • Fine-tune skills in the delivery of outpatient bispecifics
  • Gain insights to expedite reimbursements for outpatient bispecifics

Learning Objectives

  1. Summarize the current clinical applications of bispecific antibodies in the treatment of patients with cancer.
  2. Discuss efficacy and expected outcomes with patients who are considering treatment with a bispecific antibody.
  3. Implement appropriate dosing and administration strategies for patients undergoing treatment with bispecific antibodies in the inpatient and outpatient settings.
  4. Manage treatment-related adverse events associated with bispecific antibody therapy. 

Target Audience

This activity is designed to educate the multidisciplinary team including academic and community hematologists, oncologists, and hem/onc APPs, including nurse practitioners, physician assistants, pharmacists, and nurse specialists.

ATTENTION:  This limited-seating event is open exclusively for clinicians actively practicing in oncology as well as those cancer center employees directly involved in the design and development of outpatient clinics where bispecifics are administered to patients.  No pharmaceutical representatives will be seated for this event and their registrations will be declined.  We thank you for your understanding.

This program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc. and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. 

Privacy Statement: For online registration, we take precautions to protect your information. When you submit sensitive information via the website, your information is protected both online and offline. In order to use this website, a user must first complete the registration form. During registration, a user is required to give certain information (such as name, email, mailing address, and payment information). This information is confidential and will only be used to contact you regarding your registration.

Course summary
Available credit: 
  • 2.00 ACPE Pharmacy
    The Washington State Pharmacy Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This conference is approved for up to 2.00 credit by the Washington State Pharmacy Association.

    This activity is approved for up to 2.00 credit by the Washington State Pharmacy Association. Activity Type: Live| Start/End date: Wed, 09/17/2025 - 4:30pm-Wed, 09/17/2025 - 6:30pm The Washington State Pharmacy Association (WSPA) is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education. NOTE FOR PHARMACISTS: It is the responsibility of the pharmacist or pharmacy technician to provide the correct information [NABP eProfile ID and DOB (in MMDD format)] within the evaluation, in order to receive credit for participating in this CPE activity. Following the activity’s end date, there is a maximum of 60 days allowed to upload the CPE information to the CPE Monitor. WSPA will upload the CPE information to the CPE monitor 60 days after the activity - please check your CPE Monitor at this time to ensure the CPE is uploaded in your profile. If you encounter any CPE problems, please contact WSPA at 425- 228-7171
  • 2.00 AMA PRA Category 1 Credit

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

    Horizon CME designates this Live activity for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 2.00 ANCC
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. Upon completion, NPs and RNs will be awarded up to 2.00 credit.
  • 0.75 Pharmacology
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. Upon completion, NPs and RNs will be awarded up to 0.75 credit.
Course opens: 
07/28/2025
Course expires: 
10/18/2025
Event starts: 
09/17/2025 - 4:30pm PDT
Event ends: 
09/17/2025 - 6:30pm PDT
Cost:
$0.00
Rating: 
0

Commercial support:  This program is supported by independent educational grants from Regeneron Pharmaceuticals, Inc. and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Please note: times are subject to change. Please check the syllabus for the most current version of the agenda upon arriving at the summit.

All Times Listed are for the Mountain Standard Time Zone

Wednesday, September 17, 2025

6:30pmWelcome & Introductions
6:40pmBispecific Antibodies: Past, Present, and Future
» Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, FAPO - Assistant Professor of Pharmacy - Mayo Clinic College of Medicine
6:55pmMitigation and Management of Bispecific Antibody Toxicities in Myeloma & Lymphoma
» Jennie Goble, DMSc, PA-C - Assistant Professor of Medicine - Mayo Clinic
  7:20pmPanel Discussion: Anticipating Toxicities with Bispecific Antibody Therapy
  » Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, FAPO - Assistant Professor of Pharmacy - Mayo Clinic College of Medicine
  » Jennie Goble, DMSc, PA-C - Assistant Professor of Medicine - Mayo Clinic
  » Jonathan Ticku, MD - Assistant Professor of Oncology - Mayo Clinic Health System
  » Gordon J. Ruan, MD - Oncology & Hematology - HealthPartners Park Nicollet
7:35pmEffective Implementation of Bispecific Antibodies
» Jonathan Ticku, MD - Assistant Professor of Oncology - Mayo Clinic Health System
  8:00pm  Panel Discussion: Operationalizing Bispecific Antibody Delivery
  » Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, FAPO - Assistant Professor of Pharmacy - Mayo Clinic College of Medicine
  » Jennie Goble, DMSc, PA-C - Assistant Professor of Medicine - Mayo Clinic
  » Jonathan Ticku, MD - Assistant Professor of Oncology - Mayo Clinic Health System
  » Gordon J. Ruan, MD - Oncology & Hematology - HealthPartners Park Nicollet
8:20pmKey Takeaways and Final Audience Q&A
CRAVE
8251 Flying Cloud Drive #310
Eden Prairie, MN 55344
United States

 

 

Faculty Presenters


 

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, FAPO
 

Assistant Professor of Pharmacy
Mayo Clinic College of Medicine
Rochester, MN
Director of Pharmcacy
Minnesota Oncology
Minneapolis, MN


Jennie Goble, DMSc, PA-C

Assistant Professor of Medicine
Mayo Clinic
Rochester, MN

Jennie Goble is a Physician Assistant in the Division of Hematology at Mayo Clinic in Rochester, MN. She is an Assistant Professor in the College of Medicine and has a Doctorate in Medical Sciences with emphasis in PA Education. Jennie has been a Physician Assistant in Hematology for 13 years and has practiced in both the inpatient and hospital outpatient settings. She is also a Clinical Co-Director of Development for the Mayo Clinic PA Program. She is a fellow member of the Academy of Educational Excellence. She is integral to education and mentoring of new providers. Clinical interests include acute leukemia, high grade lymphoma, cancer supportive care, and elderly oncology. Her passions are high quality patient care, NPPA education, and quality improvement.


 

Jonathan Ticku, MD

Assistant Professor of Oncology
Mayo Clinic Health System
Rochester, MN

 


 

Gordon J. Ruan, MD

Oncology & Hematology
HealthPartners Park Nicollet
Bloomington, MN


Program Planning Committee


Charie Gleason, MSN, NP-BC, AOCNP (Content Co-Chair)

VP and Chief APP Officer, Adjunct Faculty

Nell Hodgson Woodruff School of Nursing

Emory Healthcare

Atlanta, GA

Charise Gleason, MSN, NP-BC, AOCNP®, is the VP and Chief Advanced Practice Officer for Emory Healthcare and adjunct faculty at the Nell Hodgson Woodruff School of Nursing at Emory University. She has been a nurse practitioner in the Multiple Myeloma program at the Winship Cancer Institute of Emory University for over twenty years. She earned both her bachelor’s and master’s degrees from Emory University and holds an advanced oncology certification through the ONCC. Ms. Gleason has been an active presenter and educator on the topics of multiple myeloma and has authored or co-authored many publications, including book chapters, abstracts, articles for nursing journals, and scientific publications.


Jesus G. Berdeja, M.D. (Content Co-Chair)

Director of Multiple Myeloma Research

The Greco-Hainsworth Tennessee Oncology Centers for Research

Nashville, TN

Jesus G. Berdeja received his undergraduate degree from Stanford University and medical degree from Harvard University. He completed his internship and residency in the Department of Internal Medicine at the University of California in San Francisco and fellowships in medical oncology and hematology at Johns Hopkins University School of Medicine in Baltimore.

Dr. Berdeja specializes in clinical hematology, with a focus on multiple myeloma. Additionally, he is an active member of several professional organizations, including the International Myeloma Society, the American Society of Clinical Oncology, the American Society of Hematology, the International Myeloma Working Group and the Clinical Trials Myeloma Intergroup Committee. An active researcher, Dr. Berdeja has been the principal investigator many funded clinical trials in the field of multiple myeloma. He has published extensively in the peer-reviewed literature and is a frequent invited lecturer.


Disclosures:


Those others involved in the planning of this activity disclosed no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

Other Contributors

All other non-faculty contributors and others involved in the planning, development and editing/review of the content disclosed no relevant financial relationships with any entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients.

 

Charise Gleason, MSN, NP-C, AOCNP discloses no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients during the past 24 months.

Jesús G. Berdeja, M.D. discloses contracted research with 2 Seventy Bio, Abbvie, Amgen, BMS, C4 Therapeutics, Caribou Biosciences, CARsgen, Cartesian Therapeutics, Celularity, CRISPR Therapeutics, Fate Therapeutics, Genentech, GSK, Ichnos Sciences, Incyte, Janssen, Juno Therapeutics, K36 Therapeutics. Karyopharm, Lilly, Novartis, Poseida, Roche, Sanofi, Takeda, Consulting Fee's with AstraZeneca, BMS, Caribou Biosciences, Galapagos, Janssen, K36 Therapeutics, Kite Pharma, Legend Biotech, Pfizer, Regeneron, Roche, Sanofi, Sebia, Takeda and Speaker's Honoraria with Janssen during the past 24 months. 

 

Available Credit

  • 2.00 ACPE Pharmacy
    The Washington State Pharmacy Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This conference is approved for up to 2.00 credit by the Washington State Pharmacy Association.

    This activity is approved for up to 2.00 credit by the Washington State Pharmacy Association. Activity Type: Live| Start/End date: Wed, 09/17/2025 - 4:30pm-Wed, 09/17/2025 - 6:30pm The Washington State Pharmacy Association (WSPA) is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education. NOTE FOR PHARMACISTS: It is the responsibility of the pharmacist or pharmacy technician to provide the correct information [NABP eProfile ID and DOB (in MMDD format)] within the evaluation, in order to receive credit for participating in this CPE activity. Following the activity’s end date, there is a maximum of 60 days allowed to upload the CPE information to the CPE Monitor. WSPA will upload the CPE information to the CPE monitor 60 days after the activity - please check your CPE Monitor at this time to ensure the CPE is uploaded in your profile. If you encounter any CPE problems, please contact WSPA at 425- 228-7171
  • 2.00 AMA PRA Category 1 Credit

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

    Horizon CME designates this Live activity for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 2.00 ANCC
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. Upon completion, NPs and RNs will be awarded up to 2.00 credit.
  • 0.75 Pharmacology
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. Upon completion, NPs and RNs will be awarded up to 0.75 credit.

Price

Cost:
$0.00
Please login or register to take this course.

ATTENTION:  This limited-seating event is open exclusively for clinicians actively practicing in oncology as well as those cancer center employees directly involved in the design and development of outpatient clinics where bispecifics are administered to patients.  No pharmaceutical representatives will be seated for this event and their registrations will be declined.  We thank you for your understanding.